Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Retacrit [legacy through FY23] by Year
Retacrit (epoetin alfa biosimilar) [legacy through FY23] — U.S. revenues ($M) ($M)
Pfizer Retacrit [legacy through FY23]: $259M in FY2023, down 17.0% from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
“|| Retacrit | 340 | 394 | (14%) | (14%) | 259 | 312 | (17%) | 81 | 82 | (1%) | (2%)”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Retacrit (epoetin alfa biosimilar) [legacy through FY23] — U.S. revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 259 | -17.0% | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2022 | Dec 31, 2022 | 312 | -9.3% | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2021 | Dec 31, 2021 | 344 | +23.7% | Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗ |
| FY2020 | Dec 31, 2020 | 278 | +97.2% | Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗ |
| FY2019 | Dec 31, 2019 | 141 | +2,250.0% | Form 8-K (Earnings / Guidance Release) (pfe-12312020xex99.htm, filed 2021-02-02) ↗ |
| FY2018 | Dec 31, 2018 | 6 | – | Form 8-K (Earnings / Guidance Release) (pfe-12312019xex99.htm, filed 2020-01-28) ↗ |
Breakdown
What makes up retacrit [legacy through FY23]
Cite this data
StockData. (2026). Pfizer Retacrit [legacy through FY23] ($M), annual FY2018–FY2023 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/retacrit-leg-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.